GlobeNewswire

AB Linas Agro Group performance and financial results for the three months of 2020/21

Share

Consolidated revenue went up 60% to EUR 239 million. Sales volume in tons reached 769 thousand tons of various products and was 75% more as compared to previous year.

The gross profit reached EUR 13.2 million and was 26% higher than a year before. Consolidated EBITDA was 92% higher and amounted to EUR 9.2 million. The operating profit was EUR 4.9 million or 260% higher.
Profit before taxes amounted to EUR 4.5 million against EUR 0.9 million in previous year. The net profit attributable to the Company went up from EUR 0.6 million to EUR 3.9 million.

A commentary by Mažvydas Šileika, Financial Director of AB Linas Agro Group:

"A good harvest has helped to achieve very good trading results, and poultry business was the one most affected by the global pandemic.

Revenue from trade in grain, oilseeds and feedstuff increased by 100% over the year to EUR 172 million, and operating profit amounted to EUR 3.3 million being 4.7 times higher.

Due to the successful growing season, our customers-farmers also recovered, their financial situation became more stable, therefore they increased investments in new crops, and updated their agricultural machinery fleet. Products and services for farming generated EUR 48 million or 15% higher income and 111% higher operating profit – EUR 2 million. Sales of seeds and plant care products grew by 4% and 27%, respectively, sales of fertilizers remained at the same level and sales of agricultural machinery increased by 32%. Grain preparation and farm equipment installation projects generated three times more revenue than in previous year.

Agricultural companies produced 40% more crop production and 8% more milk than in the same period last year, their sales revenue increased by 18% to EUR 11 million, and operating loss decreased by 97% to EUR 0.4 million.

We have faced the biggest challenge in poultry business, as the HORECA sector in various European countries has not fully recovered as a result of the pandemic, and surplus production has pushed down prices. Revenue from these activities decreased by 12% to EUR 17 million, and operating profit went down 88% to EUR 0.16 million."

ENCL.:
AB Linas Agro Group Consolidated unaudited Financial Statements and Interim Activity Report for the three months period ended 30 September 2020.


Mažvydas Šileika, Finance Director of AB Linas Agro Group
Mob. +370 619 19 403
E-mail m.sileika@linasagro.lt

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform22.1.2021 14:00:00 CETPress release

Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide. BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more efficient

Corr: SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 13:23:24 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Korr: SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 13:23:24 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

PCI Biotech to present at RNA Therapeutics Virtual Conference22.1.2021 12:04:15 CETPress release

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event. On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies. The presentation slides will be made available t

SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 10:47:43 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 10:47:43 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)